歌礼(01672.HK)午後挫22% 内地医保名单三种丙肝药降价八成
内地公布医保药品名单,新增70个药品平均降价60.7%,其中三种丙肝治疗用药降幅平均更超过85%,肿瘤及糖尿病等治疗药物平均降价约65%。
相关股今天以目前只有两款分别治疗丙肝「戈诺卫」及乙肝「派罗欣」药物上市的歌礼制药-B(01672.HK)表现最差,股价午後跌幅由半日市不足一成,扩至最多急挫22.6%,一举失守四条移动平均(50天及百天线分别为3.63元及4.05元),最低见3.53元,现造3.54元,急挫22%,成交急增至1,844万股,涉资7,276万元。
有研发肿瘤药的绿叶制药(02186.HK)曾失守100天、250天及50天线(6.03-6.08元),最低见5.89元,现造6.05元,续跌3.5%,成交倍增至2,842万股,涉资1.71亿元。不过,金斯瑞生物(01548.HK)逆市反覆回升3.2%报19.58元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.